 |
|
|
|
|
 |
Last Updated: Nov 1, 2009 - 11:48:48 PM |
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
FDA approves extended dosing of Aranesp
Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced the U.S. Food and Drug Administration (FDA) has approved every-three-week dosing of Aranesp® (darbepoetin alfa) for the treatment of chemotherapy-induced anemia (low red blood cell count) in patients with non-myeloid malignancies. Aranesp is the only erythropoiesis-stimulating agent approved by the FDA for every-three-week administration.
Mar 28, 2006 - 7:58:37 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Study Suggests Drug For Chemotherapy-Induced Anemia Can Be Effectively Administered Tri-Weekly
Parallel administration of chemotherapy and an anti-anemia drug called darbepoetin alfa every 3 weeks is safe and effective, according to a new study.
Feb 15, 2006 - 8:00:37 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Interim Aranesp data suggest major response in anemic patients with MDS
Amgen (NASDAQ: AMGN), the world's largest biotechnology company, today announced updated interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp darbepoetin alfa) administered every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndrome (MDS). Low-risk MDS patients receiving Aranesp every three weeks, who had no prior erythropoietic therapy, exhibited an overall response of 70 percent, increased hemoglobin levels and improvements in patient-reported fatigue.
Dec 13, 2005 - 8:05:38 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Interim data suggest major response with Aranesp(R) in anemic patients with MDS
Amgen Inc. (NASDAQ:AMGN), the world's largest biotechnology company, today announced new interim data from a Phase 2 study evaluating the use of 500 mcg of Aranesp(R) (darbepoetin alfa) every three weeks to treat anemia in patients with a bone marrow disorder known as myelodysplastic syndromes (MDS). The data were presented at the 17th International Symposium of the Multinational Association of Supportive Care in Cancer (MASCC) in Geneva. (Abstract #02-007)
Jul 10, 2005 - 8:16:38 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Aranesp dosed every three weeks achieved and maintained target hemoglobin levels
Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that new interim data from a single-arm, open label study of 1,225 cancer patients receiving chemotherapy demonstrated that Aranesp® (darbepoetin alfa) administered every three weeks was effective in increasing and maintaining patient hemoglobin levels to the recommended target of greater than or equal to 11 g/dL. Further, treatment with Aranesp reduced the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia.
May 16, 2005 - 8:26:38 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Final results demonstrate Aranesp dosed every two weeks is comparable to Epoetin alfa dosed weekly
Amgen Inc., (NASDAQ: AMGN) the world's largest biotechnology company, today announced that final results of a Phase 3 randomized, head-to-head study demonstrated that 200 mcg of Aranesp® (darbepoetin alfa) administered every two weeks is as effective as 40,000 U of Epoetin alfa dosed once a week in boosting hemoglobin levels and reducing the need for red blood cell transfusions in cancer patients with chemotherapy-induced anemia.
May 16, 2005 - 8:22:38 PM
|
Latest Research
:
Haematology
:
Anaemia
:
Darbepoetin Alfa
Anemia drug reduces transfusions and chemotherapy-related fatigue
Patients treated with darbepoetin alfa (AranespTM) for chemotherapy-induced anemia may require fewer blood transfusions and feel less fatigued than patients receiving a placebo, concludes a new study in the August 21 issue of the Journal of the National Cancer Institute.
Aug 28, 2002 - 8:14:38 PM
|
<< prev
next >>
|
|
|
|
